{
  "generatedAt": "2026-10-17T12:23:42.208Z",
  "rulesVersion": "1.56",
  "sources": [
    {
      "id": "ema-cpca-appendix-2",
      "issuer": "EMA",
      "docName": "Appendix 2 — Carcinogenic Potency Categorisation Approach",
      "version": "EMA/451665/2023",
      "docDate": "2023-10-12",
      "url": "https://www.ema.europa.eu/en/documents/other/appendix-2-carcinogenic-potency-categorisation-approach-n-nitrosamines_en.pdf",
      "lastChecked": "2026-10-16",
      "usedBy": [
        "nitrosamine-limit-calculator"
      ]
    },
    {
      "id": "fda-ndsri-guidance",
      "issuer": "FDA",
      "docName": "Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities",
      "version": "Aug 2023",
      "docDate": "2023-08-04",
      "url": "https://www.fda.gov/media/170794/download",
      "lastChecked": "2026-10-17",
      "usedBy": [
        "nitrosamine-limit-calculator"
      ]
    },
    {
      "id": "fda-cder-ai-limits",
      "issuer": "FDA",
      "docName": "CDER Nitrosamine Impurity Acceptable Intake Limits",
      "version": "Updated information (living list)",
      "docDate": "2026-09-24",
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cder-nitrosamine-impurity-acceptable-intake-limits",
      "lastChecked": "2026-10-17",
      "usedBy": [
        "nitrosamine-limit-calculator"
      ]
    },
    {
      "id": "ema-nitrosamine-qa",
      "issuer": "EMA",
      "docName": "Questions and answers for MAHs/applicants on the CHMP Opinion for the Article 5(3) referral on nitrosamine impurities in human medicinal products",
      "version": "EMA/409815/2020 Rev.23",
      "docDate": "2025-10-10",
      "url": "https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/nitrosamines-emea-h-a53-1490-questions-answers-marketing-authorisation-holders-applicants-chmp-opinion-article-53-regulation-ec-no-726-2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf",
      "lastChecked": "2026-10-17",
      "usedBy": [
        "nitrosamine-limit-calculator"
      ]
    },
    {
      "id": "ich-m7-r2",
      "issuer": "ICH",
      "docName": "Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk",
      "version": "M7(R2)",
      "docDate": "2023-04-03",
      "url": "https://database.ich.org/sites/default/files/ICH_M7%28R2%29_Guideline_Step4_2023_0216.pdf",
      "lastChecked": "2026-10-17",
      "usedBy": [
        "nitrosamine-limit-calculator"
      ]
    },
    {
      "id": "ich-q3c-r9",
      "issuer": "ICH",
      "docName": "Impurities: Guideline for Residual Solvents",
      "version": "Q3C(R9)",
      "docDate": "2024-01-24",
      "url": "https://database.ich.org/sites/default/files/ICH_Q3C(R9)_Guideline_MinorRevision_2024_2024_Approved.pdf",
      "lastChecked": "2026-10-17",
      "usedBy": [
        "residual-solvent-limit-calculator"
      ]
    },
    {
      "id": "ema-q3c-r9",
      "issuer": "EMA",
      "docName": "ICH Q3C(R9) residual solvents scientific guideline",
      "version": "Q3C(R9)",
      "docDate": "2024-04-29",
      "url": "https://www.ema.europa.eu/en/scientific-guidelines/ich-q3c-r9-residual-solvents",
      "lastChecked": "2026-10-17",
      "usedBy": [
        "residual-solvent-limit-calculator"
      ]
    },
    {
      "id": "usp-467",
      "issuer": "USP",
      "docName": "Residual Solvents",
      "version": "<467> (official 1 Aug 2025)",
      "docDate": "2025-08-01",
      "url": "https://doi.org/10.31003/USPNF_M99226_09_01",
      "lastChecked": "2026-10-17",
      "usedBy": [
        "residual-solvent-limit-calculator"
      ]
    }
  ]
}